EUVIMEDEUVIMED entdecken
Crossref

O16 Erlotinib in pachyonychia congenita

Elena Giusto, Marianne De Brito, Edel O’Toole

British Journal of Dermatology · 23.06.2026 · 195 (1)

DOI: 10.1093/bjd/ljag151.016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Dermatology, online erschienen am 23.06.2026. Verfasst von Elena Giusto und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and aims Pachyonychia congenita (PC) is a rare inherited skin disorder within the palmoplantar epidermal differentiation disorders (pEDDs), recently reclassified by genotype as KRT6A/KRT6B/KRT6C/KRT16/KRT17-pEDD. Patients experience painful plantar calluses and severe, disabling foot pain. PC keratinocytes exhibit increased epidermal growth factor receptor (EGFR) expression. Erlotinib, an EGFR inhibitor approved for metastatic cancer in the UK, has shown anecdotal benefit in reducing pain and improving function in patients with PC (n = 6). This study aimed to assess the effect of erlotinib effects on PC-derived keratinocyte cell lines in two-dimensional and three-dimensional (3D) culture.

Methods

Western blot analysis was used to evaluate EGFR and its phosphorylation in wildtype (WT) and PC keratinocytes with and without EGF or erlotinib. 3D skin equivalents were generated for immunostaining of differentiation markers. Callus samples from a patient with KRT16-pEDD, pre- and post-erlotinib treatment (4 months), underwent phosphoproteomic analysis and pathway analysis.

Results

The KRT16-pEDD cell line demonstrated heightened EGF responsiveness and elevated baseline phospho-ERK. Erlotinib reduced p-ERK by 36% at 1–10 nmol L–1 and by 87% at 1 μmol L–1. In 3D models, KRT6A(N171K) epidermis showed acanthosis and disordered differentiation, which normalized at 100 nmol L–1 erlotinib, restoring involucrin to the upper epidermis. Phosphoproteomics revealed post-treatment changes in differentiation/cornification and BRAF pathway enrichment, indicating compensatory signalling following EGFR inhibition.

Conclusions

Erlotinib effectively attenuates EGFR signalling in PC keratinocytes, normalizing epidermal architecture and differentiation in 3D models. Phosphoproteomic changes suggest compensatory BRAF pathway activation, which may cause therapeutic resistance. These findings support EGFR inhibition as a potential therapeutic approach for PC and warrant placebo-controlled trials.

Zitieren

APA

Giusto, E., Brito, M. D., & O’Toole, E. (2026). O16 Erlotinib in pachyonychia congenita. British Journal of Dermatology, 195(1). https://doi.org/10.1093/bjd/ljag151.016

Vancouver

Giusto E, Brito MD, O’Toole E. O16 Erlotinib in pachyonychia congenita. British Journal of Dermatology. 2026;195(1). doi:10.1093/bjd/ljag151.016

BibTeX
@article{Giusto2026,
  author = {Giusto, Elena and Brito, Marianne De and O’Toole, Edel},
  title = {O16 Erlotinib in pachyonychia congenita},
  journal = {British Journal of Dermatology},
  year = {2026},
  volume = {195},
  number = {1},
  doi = {10.1093/bjd/ljag151.016}
}
Kostenlos starten →